Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.

Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S.

J Pharmacol Exp Ther. 1996 Feb;276(2):398-404.

PMID:
8632302
2.

Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

Zocchi C, Ongini E, Ferrara S, Baraldi PG, Dionisotti S.

Br J Pharmacol. 1996 Apr;117(7):1381-6.

3.

Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models.

Dionisotti S, Conti A, Sandoli D, Zocchi C, Gatta F, Ongini E.

Br J Pharmacol. 1994 Jun;112(2):659-65.

4.

Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.

Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm BB.

Br J Pharmacol. 1997 Jun;121(3):353-60.

5.

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.

Baraldi PG, Cacciari B, Spalluto G, Pineda de las Infantas y Villatoro MJ, Zocchi C, Dionisotti S, Ongini E.

J Med Chem. 1996 Mar 1;39(5):1164-71.

PMID:
8676354
6.

The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, Coll MG.

Br J Pharmacol. 1995 Jul;115(6):1096-102.

8.

Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.

Monopoli A, Casati C, Lozza G, Forlani A, Ongini E.

J Pharmacol Exp Ther. 1998 Apr;285(1):9-15.

9.

Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine.

Monopoli A, Conti A, Zocchi C, Casati C, Volpini R, Cristalli G, Ongini E.

Arzneimittelforschung. 1994 Dec;44(12):1296-304.

PMID:
7848347
10.

Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.

Dionisotti S, Ferrara S, Molta C, Zocchi C, Ongini E.

J Pharmacol Exp Ther. 1996 Sep;278(3):1209-14.

PMID:
8819504
11.

[3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies.

Fredholm BB, Lindström K, Dionisotti S, Ongini E.

J Neurochem. 1998 Mar;70(3):1210-6.

12.

[3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes.

Varani K, Gessi S, Dionisotti S, Ongini E, Borea PA.

Br J Pharmacol. 1998 Apr;123(8):1723-31.

13.

Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes.

Belardinelli L, Shryock JC, Ruble J, Monopoli A, Dionisotti S, Ongini E, Dennis DM, Baker SP.

Circ Res. 1996 Dec;79(6):1153-60.

14.

G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.

Cunha RA, Constantino MD, Ribeiro JA.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Apr;359(4):295-302.

PMID:
10344528
15.

Selective adenosine A2A receptor antagonists.

Ongini E, Monopoli A, Cacciari B, Baraldi PG.

Farmaco. 2001 Jan-Feb;56(1-2):87-90. Review.

PMID:
11347973
16.
17.
18.

1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells.

Belardinelli L, Shryock JC, Zhang Y, Scammells PJ, Olsson R, Dennis D, Milner P, Pfister J, Baker SP.

J Pharmacol Exp Ther. 1995 Dec;275(3):1167-76.

PMID:
8531078
19.

Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding.

Varani K, Gessi S, Dalpiaz A, Ongini E, Borea PA.

Br J Pharmacol. 1997 Sep;122(2):386-92.

20.

Adenosine receptors involved in modulation of noradrenaline release in isolated rat tail artery.

Diniz C, Fresco P, Leal S, Gonçalves J.

Eur J Pharmacol. 2004 Nov 3;504(1-2):17-25.

PMID:
15507216

Supplemental Content

Support Center